Hosted on MSN6mon
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Biotech stocks are high-risk ... the stock prices of the respective companies in an appreciable manner. 1. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Date: Tuesday, June 25 Catalyst: Discussion ...
Equities Analysts Set Expectations for ARWR FY2025 Earnings
B. Riley upped their FY2025 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a report issued on ...
Nasdaq1mon
Arrowhead Pharma Inks Licensing Deal With Sarepta, Stock Jumps
(RTTNews) - Arrowhead Pharmaceuticals (ARWR), a clinical-stage biotech company, announced, on Tuesday, that it has entered into a global licensing and collaboration agreement with Sarepta ...
ETF Daily News5d
Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Price Target at $43.33
Avoro Capital Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 3.9% in the second quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s ...
BioSpace4d
Sarepta Previews Q4 Findings, Touts Elevidys Earnings Beat
Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...
Investing11d
Arrowhead Pharmaceuticals' chief sells $648,824 in stock
PASADENA, Calif.—Hamilton James C, Chief of Discovery/Trans Medicine at Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biotechnology company currently valued at $2.45 billion, sold a ...